Related Projects
The AutoCRAT team have close connections with other projects and initiatives working in regenerative medicine and life sciences engineering. Some of these initiatives are set out below.
AUTOSTEM: The full title of the AUTOSTEM Project was “Development of closed, scalable and automated robotic systems for therapeutic stem cell manufacturing: aseptic systems from Donor-to-Patient”. AUTOSTEM was a H2020 EU funded project which ran from 1 January 2016 to 31 December 2018. AUTOSTEM and AutoCRAT have some common partners and AUTOSTEM will form an important building block for the AutoCRAT Regenerative Medicine Factory (ARM-F). Prof. Mary Murphy of NUIG (Coordinator of AutoCRAT) was also the Coordinator of AUTOSTEM.
ADIPOA 2: This EU H2020 Project is carrying out a phase IIb study to assess the safety and efficacy of autologous (patient-derived) mesenchymal stromal cells in the treatment of advanced OA of the knee. The Project runs from 1 January 2015 to 31 December 2019. ADIPOA-2 and AutoCRAT have some common partners. NUIG is Coordinator.
VISICORT: This EU H2020 Project explores the use of stromal cell therapy for the prevention of adverse immune responses in recipients of high-risk corneal transplants. The Project runs from 1 April 2014 to 30 September 2020 and shares some common partners with AutoCRAT. NUIG is Coordinator.
NEPHSTROM: This EU H2020 Project explores the treatment of diabetic kidney disease with a purified population of Mesenchymal Stromal Cells (MSCs) from human bone marrow. The Project runs from 1 May 2015 to 31 October 2020 and has some common partners with AutoCRAT. NUIG is Coordinator.
STARSTEM: This EU H2020 Project is using fundamental advances in the physics of imaging to validate stem cell treatments for arthritis. STARSTEM runs from 1 January 2018 to 31 December 2021 and shares common partners with AutoCRAT. NUIG is Coordinator.
STEMCELLFACTORY III: This project is funded through the European Regional Development Fund and is developing methods for the automated production of patient- and disease-specific induced pluripotent stem cells (iPS cells) from easy-to-obtain blood samples. The Project runs from 1 July 2017 to 30 June 2020 and is coordinated by AutoCRAT partner Fraunhofer IPT.